retatrutide obesity triple hormone receptor agonist for diabetes type 2 metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide is gaining attention in – Lilly's triple G agonist boasts

doi: 10.1002/dvg.23455

Results guide personalized dosing strategies and help your provider select between semaglutide, tirzepatide, or dual-compound options (GLP-Squared) that match your genetic profile

Say goodbye to white marks on your clothes and greasy residues

This pen injector platform provides a precise dosage range from 0.01ml up to 0.6ml, ensuring maximum dosing flexibility for various therapeutic protocols across a wide spectrum of patient requirements

Notably, although there was not a statistically significant increase in biliary disease among GLP-1 receptor agonist users in this study, the FDA 2 added warnings and precautions about acute cholecystitis and biliary disease to the label in late 2022 based on data from placebo-controlled RCTs as well as other observational data 3